Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

New Insights into Endogenous Retrovirus-K Transcripts in Amyotrophic Lateral Sclerosis

  • Moreno-Martinez, Laura
  • Macías-Redondo, Sofía
  • Strunk, Mark
  • Guillén-Antonini, María Isabel
  • Lunetta, Christian
  • Tarlarini, Claudia
  • Penco, Silvana
  • Calvo, Ana Cristina
  • Osta, Rosario
  • Schoorlemmer, Jon
Retroviral reverse transcriptase activity and the increased expression of human endogenous retroviruses (HERVs) are associated with amyotrophic lateral sclerosis (ALS). We were interested in confirming HERVK overexpression in the ALS brain, its use as an accessory diagnostic marker for ALS, and its potential interplay with neuroinflammation. Using qPCR to analyze HERVK expression in peripheral blood mononuclear cells (PBMCs) and in postmortem brain samples from ALS patients, no significant differences were observed between patients and control subjects. By contrast, we report alterations in the expression patterns of specific HERVK copies, especially in the brainstem. Out of 27 HERVK copies sampled, the relative expression of 17 loci was >1.2-fold changed in samples from ALS patients. In particular, the relative expression of two HERVK copies (Chr3-3 and Chr3-5) was significantly different in brainstem samples from ALS patients compared with controls. Further qPCR analysis of inflammation markers in brain samples revealed a significant increase in NLRP3 levels, while TNFA, IL6, and GZMB showed slight decreases. We cannot confirm global HERVK overexpression in ALS, but we can report the ALS-specific overexpression of selected HERVK copies in the ALS brain. Our data are compatible with the requirement for better patient stratification and support the potential importance of particular HERVK copies in ALS.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The placental transcriptomic profile determined by maternal COVID-19 disease encompasses alterations reminiscent of preeclampsia

  • Medel-Martinez, Ana
  • Strunk, Mark
  • Cebollada-Solanas, Alberto
  • Puente-Santamaría, Laura
  • Gómez-Muñoz, Sonia
  • Fabre, Marta
  • Paules, Cristina
  • Oros, Daniel
  • Schoorlemmer, Jon
Introduction. During initial stages of the pandemic, SARS-CoV-2 infection during pregnancy was related to adverse pregnancy outcomes and alterations in the placenta. Whether placental abnormalities in pregnant women with COVID-19 still persist afterwards remains poorly studied. Here, we determined whether the absence of obstetric complications after maternal COVID-19 disease, including preeclampsia, is accompanied by a complete return to normalcy in terms of placental physiology. Methods. Placental RNA was purified from placental samples from SARS-CoV-2 positive mothers taken either in 2022, when Omicron was the predominant variant of concern (termed Omicron) (n = 21); or from healthy pregnancies predating the pandemic (termed preCOVID-19). Our cohort included samples from pregnant women who got infected weeks and even months before term. We performed RNA-seq, identified differentially expressed genes and examined to which biological, biochemical and cellular pathways they belong, using gene set enrichment analysis. Results. We identified 71 differentially expressed genes (DEGs) (defined by p-value ≤0.05 and fold change (FC) of ≤ -2 or ≥2). The alterations identified in placentas delivered by mothers who suffered an episode of COVID-19 disease could be mainly attributed to pathways related to organogenesis, extracellular matrix organization and oxygen transport. These alterations were also detected after exclusion of gestational diabetes mellitus (GDM) samples. Although none of the samples were taken from cases of preeclampsia, several of the relevant DEGs have been previously reported as dysregulated in hypertensive disorders of pregnancy including preeclampsia. Discussion. We propose that maternal SARS-CoV-2 infection causes alterations in gene expression that are indicative of vascular defects in the placenta
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Urinary placental growth factor stability as a critical factor in the reliability of preeclampsia diagnosis

  • Martinez-Marzo, Eva
  • Peran, Maria
  • Lerma-Irureta, Juan
  • Medel-Martinez, Ana
  • Paules, Cristina
  • Oros, Daniel
  • Fabre, Marta
Introduction: Placental growth factor (PlGF) is a key biomarker for diagnosing and predicting preeclampsia (PE). While serum-based PlGF assays are well established, urine has emerged as a promising non-invasive alternative matrix. However, the absence of urinary PlGF stability data remains a major preanalytical limitation. This study aimed to assess urinary PlGF stability under common preanalytical conditions, including refrigerated storage and a double freeze-thaw cycle. Materials and methods: A prospective study was conducted using urine samples from ten pregnant women. Each sample was processed under standard laboratory conditions and aliquoted into five tubes. One aliquot was immediately frozen at - 80 °C (T0), three were stored at 2-8 °C for 48, 96, and 168 hours before freezing, and one underwent a double freeze-thaw cycle. Urinary PlGF concentrations were measured using the Elecsys PlGF immunoassay on Roche Cobas e801 analyzer. Percent degradation (PD%) was calculated relative to baseline. A linear regression model was applied to estimate the time to exceed a maximum permissible instability (MPI) of ± 10 %. Results: Urinary PlGF remained stable at 2-8 °C for up to 48 hours, with a mean PD% of - 6 % (95% confidence interval (CI): - 9.1 to - 2.8). The regression model (PD% = - 0.0834 x Time (h)) estimated the - 10 % threshold at approximately 120 hours. After a double freeze-thaw cycle, the mean PD% was - 1.5 % (95% CI: - 3.4 to 0.4%). Conclusions: Urinary PlGF shows acceptable stability for up to 48 hours under refrigeration and is stable over two freeze-thaw cycles. These findings provide essential preanalytical data supporting its potential use in clinical and research settings.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Towards an understanding of COVID-19-associated preeclampsia

  • Medel-Martinez, A.
  • Cebollada-Solanas, A.
  • Strunk, M.
  • Fabre, M.
  • Fernández-Soria, V. M.
  • Ramos-Ruiz, R.
  • Paules, C.
  • Oros, D.
  • Schoorlemmer, J.
Introduction SARS-CoV-2 infection during pregnancy has been associated with higher rates of preeclampsia (PE). While placental abnormalities resembling PE have been reported in COVID-19 pregnancies, the molecular mechanisms underlying the association remain unclear. Methods We conducted bulk RNA sequencing on placental tissues from four pregnancy groups: uneventful prepandemic (preCOVID-19), prepandemic PE (preCOVID-19 PE), COVID-19 without PE (COVID no PE), and COVID-19 complicated by PE or other hypertensive disorders (COVID PE). Differential expression was analyzed using Deseq2 likelihood ratio test (LRT), and gene set enrichment analysis identified dysregulated pathways. Results Clustering of LRT-significant differentially expressed genes (DEGs) identified a set of 16 genes (defined by the false discovery rate adjusted p-value < 0.05) across the four pregnancy groups, showing stepwise expression changes—lowest in preCOVID-19 uneventful, followed by those in COVID-19 without PE, then preCOVID-19 PE, and highest in COVID PE. This cluster included genes associated with placental dysfunction, such as LAMA5 and BTNL9. While morphogenesis-related pathways were enriched across all pathological groups, immune activation pathways were predominantly enriched in COVID PE, moderately in preCOVID-19 PE, and absent in COVID no PE. Discussion Our findings identify a COVID-19–associated placental signature that mirrors PE features and shows a progressive expression pattern defining a continuum of placental stress, with maternal SARS-CoV-2 infection potentially exacerbating underlying dysfunction.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Alterations of placental HERV expression as a result of gestational COVID-19 disease

  • Medel-Martinez, Ana
  • Bugatti, Mattia
  • Polychronopoulou, Mariana
  • Strunk, Mark
  • Macías-Redondo, Sofía
  • Bazo, Andrea
  • Garrido-Pontnou, Marta
  • Kitsou, Konstantina
  • Fabre, Marta
  • Paules, Cristina
  • Oros, Daniel
  • Pierquin, Justine
  • Brunel, Joanna
  • Charvet, Benjamin
  • Perron, Hervé
  • Facchetti, Fabio
  • Magiorkinis, Gkikas
  • Schoorlemmer, Jon
Introduction: Activation of human endogenous retroviral elements (HERV) is a well-documented phenomenon in inflammatory pathologies including COVID-19, with HERVW ENV frequently mentioned as a toxic protein. Given that COVID-19 during pregnancy has been associated with placental damage and a higher risk of adverse pregnancy outcomes (APOs), we investigated whether gestational COVID-19 alters placental HERV expression, and if such alterations correlate with placental damage or dysfunction. Methodology and results: We quantitively analyzed mRNA expression of HERV in placental samples using qPCR assays rigorously tested for efficiency and specificity or transcriptomic analysis. Combined qPCR and transcriptomic analyses of placentas from maternal COVID-19 cases revealed an overall trend toward reduced expression of several HERV elements, including HERVW ENV-related transcripts, with a more pronounced downregulation in SARS-CoV-2-positive placentas. HERVW ENV protein was detected by immunofluorescence in the syncytiotrophoblast (STB), co-staining with HCGβ, using conditions minimizing cross-reactivity with ERVWE1. HERVW ENV protein levels were diminished in COVID-19 patients, especially in those cases in which SARS-CoV-2 was present in the placenta. Conclusions and discussion: While HERV expression is reportedly induced in blood lymphocytes and other tissues as a response to SARS-CoV-2 infection, we detect unaltered or lower RNA levels of selected retroviral elements in the placenta of COVID-19 patients. HERVW ENV protein was present in non-COVID-19 placenta, and downregulated by maternal COVID-19 disease. The absence of HERVW ENV protein induction was confirmed by the careful study of cases with placental SARS-CoV-2 infection, as HERVW ENV was mostly absent from these samples, probably as an indirect result of placental damage. We identified two independent triggers for the downregulation of both HERVW ENV RNA and protein in placenta: maternal COVID-19 and local effects of SARS-CoV-2. Therefore, this HERV downregulation may represent part of the molecular response to placental SARS-CoV-2 infection, contributing to placental dysfunction and APOs.